• Title/Summary/Keyword: Dose report

Search Result 650, Processing Time 0.029 seconds

Comparing of the Administered Activities and the Effective Dose of the Various Pediatric Dose Formulas of Nuclear Medicine (핵의학검사의 방사성의약품 소아투여량 공식 별 투여량 및 유효선량 비교)

  • Gil, Jong-Won
    • Journal of the Korea Convergence Society
    • /
    • v.8 no.8
    • /
    • pp.147-154
    • /
    • 2017
  • The purpose of this study is to calculate and compare administered activities(MBq) and effective dose(mSv) of the various pediatric dose formulas of pediatric nuclear medicine and to provide base data for the criteria of the optimal administered activities. This study compares dosages and effective doses of 5 types of pediatric dose formulas(Clark rule, Area rule, Webster rule, Young rule, Solomon(Fried) rule) based on the dosage for adults of 2 types of radiopharmaceuticals($^{99m}Tc$-MDP, $^{99m}Tc$-Pertechnetate). The administered activities in adults, which is the criteria for calculating the Pediatric administered activities, used the value from the 'Nuclear Medicine' written by J-G Jeong & M-Ch Lee. and the administered activities by the radioactivity per effective dose(mSv/MBq) of the radiopharmaceuticals for calculating the effective dose used the value from ICRP 80 and the UNSCEAR 2008 Report. As a result of the study, the output of Young rule is the lowest, and its difference between other formulas is from minimum 1.7 times to maximum 3,4 times. The difference between administered activities of $^{99m}Tc$-MDP is maximum 309.9MBq and the effective dose is 3.76mSv. $^{99m}Tc$-Pertechnetate showed the figure at the maximum 154.9MBq and the effective dose has a difference of 5.50mSv. Since the pediatric dose formulas differ not only in administered activities but also in effective doses, the optimal administered activities have to be developed for optimization of medical radiation.

Review of Shielding Evaluation Methodology for Facilities Using kV Energy Radiation Generating Devices Based on the NCRP-49 Report

  • Na Hye Kwon;Hye Sung Park;Taehwan Kim;Sang Rok Kim;Kum Bae Kim;Jin Sung Kim;Sang Hyoun Choi;Dong Wook Kim
    • Progress in Medical Physics
    • /
    • v.33 no.4
    • /
    • pp.53-62
    • /
    • 2022
  • In this study, we have investigated the shielding evaluation methodology for facilities using kV energy generators. We have collected and analysis of safety evaluation criteria and methodology for overseas facilities using radiation generators. And we investigated the current status of shielding evaluation of domestic industrial radiation generators. According to the statistical data from the Radiation Safety Information System, as of 2022, a total of 7,679 organizations are using radiation generating devices. Among them, 6,299 facilities use these devices for industrial purposes, which accounts for a considerable portion of radiation. The organizations that use these devices evaluate whether the exposure dose for workers and frequent visitors is suitable as per the limit regulated by the Nuclear Safety Act. Moreover, during this process, the safety shields are evaluated at the facilities that use the radiation generating devices. However, the facilities that use radiating devices having energy less than or equal to 6 MV for industrial purposes are still mostly evaluated and analyzed according to the National Council on Radiation Protection and Measurements 49 (NCRP 49) report published in 1976. We have investigated the technical standards of safety management, including the maximum permissible dose and parameters assessment criteria for facilities using radiation generating devices, based on the NCRP 49 and the American National Standards Institute/Health Physics Society N.43.3 reports, which are the representative reports related to radiation shielding management cases overseas.

Estimated Additional Number of Workers and Additional Collective Dose by Reducing Dose Limits (선량한도 하향이 방사선작업인력 및 집단선량에 미치는 영향예측)

  • Ha, Chung-Woo;Na, Seong-Ho
    • Journal of Radiation Protection and Research
    • /
    • v.23 no.3
    • /
    • pp.149-157
    • /
    • 1998
  • An analysis has been performed to estimate the additional number of workers and the additional collective dose in man-cSv which would be required, nuclear industry-wide as a result of reducing individual dose limit. This analysis can be extended to the reduction in the dose limits recommended by ICRP Publ.60 and BEIR V report as well as the proposed dose limits by regulatory authorities. An industry-wide database was employed in the analysis based on a summary of industry-wide occupational radiation exposure compiled by the Korea Radioisotope Association. Correlation model was employed to compute the affects of setting specific annual individual dose limits. In this study, we have addressed worker non-productivity while in the radiation environment on a parametric or 'sensitivity analysis' basis. This alleviates the need for developing such data underlying a summation of many individual tasks at many nuclear facilities. It has the advantage that very low non-productivity assumptions can readily be defended as conservative, in that it is difficult to approach such low worker non-productivity factors even in the best of environments in any industry. On a per facility basis, for calendar year 1997, the number of workers required would be increased from 231 workers to 269 workers and collective man-cSv dose would be also increased by approximately fourteen percent if the individual dose limit was reduced to 2 cSv/y and an individual worker non-productivity fraction of 0.1 is assumed.

  • PDF

Administration Progression and Adverse Event Report of Er-Xian Decoction for Menopausal Hot Flushes: Case Report and Review of Literature (폐경기 안면홍조 증상에 대한 한약처방 이선탕의 투여경과 및 이상반응 보고 : 증례보고 및 문헌고찰)

  • Kim, Bo-min;Jo, Hee-geun
    • The Journal of Internal Korean Medicine
    • /
    • v.40 no.1
    • /
    • pp.154-163
    • /
    • 2019
  • Objective: We report on the administration progression and adverse event of Er-Xian decoction for menopausal hot flushes. A hot flush is a rapid and intense heat-dissipation reaction that involves considerable sweating, enlargement of the peripheral blood vessels, and internal body heat. Er-Xian decoction is a prescription for treating menopausal hot flush symptoms in postmenopausal women. We report administration progression and adverse event of Er-Xian decoction for menopausal hot flush. Methods: We used the Menopause Rating Scale and Menopause-Specific Quality of Life questionnaire to evaluate the progression of hot flushes, and we conducted a literature review to determine the effective dosage of Er-Xian decoction. Result: In all cases, Facial hot flushes and evaluation variables were improved by the administration of EXD. However, in Case 1, a rise of liver function indexes which may be related to EXD administration was observed. Conclusion: Considering that menopausal flushing usually lasts for several years, The resluts are meaningful that the short-term administration of EXD led to improvement of symptoms. In order to further use EXD in the future, it will be necessary to conduct follow-up studies on the subject of safety verification, such as repeated dose toxicity studies.

Analyzed the Computed Tomography Dose Index (CTDI) to the Pediatric Brain CT by Reason of the Observation for the Exposure Dose: Base on a Hospital (소아 두부 전산화단층촬영 선량지표 분석을 통한 피폭선량 모니터링: 일개병원 사례 중심으로)

  • Lee, Jae-Seung;Kim, Hyun-Jin;Im, In-Chul
    • The Journal of the Korea Contents Association
    • /
    • v.15 no.6
    • /
    • pp.290-296
    • /
    • 2015
  • The purpose of this study was to derive the proposals and to suggest the exposure dose reduction scheme on pediatric head CT scan by analyzing and comparing CT dose index (CTDI) and the national diagnostic reference levels. From January 2014 to December, 231 children under 10years who were requested a pediatric head CT scan with head injury were examined. Research methods were to research and analyze the general characteristics kVp, mA test coverage $CTDI_{vol}$ and DLP referring to dose reports and electronic medical record (EMR). As a result, 7.4%(17 patients) of the total subjects in $CTDI_{vol}$ showed a national diagnostic reference levels exceeding. For DLP 41.6%(96 patients) in excess was relatively higher than $CTDI_{vol}$. DLP was exceeded more than about 60% that is higher than the CT dose index presented by Korea Food & Drug Administration. it is cause of high DLP that scan range increased more than about 30% wider than the standard test coverage presented in Health Insurance Review & Assessment Service. In conclusion, it is able to significantly lower the dose if it is complied with checking the baseline scan range of pediatric head CT scan and appropriately adjusting the protocol.

BIOLOGICALLY-BASED DOSE-RESPONSE MODEL FOR NEUROTOXICITY RISK ASSESSMENT

  • Slikker, William Jr.;Gaylor, David W.
    • Toxicological Research
    • /
    • v.6 no.2
    • /
    • pp.205-213
    • /
    • 1990
  • The regulation of neurotoxicants has usually been based upon setting reference doses by dividing a no observed adverse effect level (NOAEL) by uncertainty factors that theoretically account for interspecies and intraspecies extraploation of experimental results in animals to humans. Recently, we have proposed a four-step alternative procedure which provides quantitative estimates of risk as a function of dose. The first step is to establish a mathematical relationship between a biological effect or biomarker and the dose of chemical administered. The second step is to determine the distribution (variability) of individual measurements of biological effects or their biomarkers about the dose response curve. The third step is to define an adverse or abnormal level of a biological effect or biomarker in an untreated population. The fourth and final step is to combine the information from the first three steps to estimate the risk (proportion of individuals exceeding on adverse or abnormal level of a biological effect or biomarker) as a function of dose. The primary purpose of this report is to enhance the certainty of the first step of this procedure by improving our understanding of the relationship between a biomarker and dose of administered chemical. Several factors which need to be considered include: 1) the pharmacokinetics of the parent chemical, 2) the target tissue concentrations of the parent chemical or its bioactivated proximate toxicant, 3) the uptake kinetics of the parent chemical or metabolite into the target cell(s) and/or membrane interactions, and 4) the interaction of the chemical or metabolite with presumed receptor site(s). Because these theoretical factors each contain a saturable step due to definitive amounts of required enzyme, reuptake or receptor site(s), a nonlinear, saturable dose-response curve would be predicted. In order to exemplify this process, effects of the neurotoxicant, methlenedioxymethamphetamine (MDMA), were reviewed and analyzed. Our results and those of others indicate that: 1) peak concentrations of MDMA and metabolites are ochieved in rat brain by 30 min and are negligible by 24 hr, 2) a metabolite of MDMA is probably responsible for its neurotoxic effects, and 3) pretreatment with monoamine uptake blockers prevents MDMA neurotoxicity. When data generated from rats administerde MDMA were plotted as bilolgical effect (decreases in hippocampal serotonin concentrations) versus dose, a saturation curve best described the observed relationship. These results support the hypothesis that at least one saturable step is involved in MDMA neurotoxicity. We conclude that the mathematical relationship between biological effect and dose of MDMA, the first step of our quantitative neurotoxicity risk assessment procedure, should reflect this biological model information generated from the whole of the dose-response curve.

  • PDF

Radiation dose and Lifetime Attributable Risk of Cancer Estimates in 64-slice Multidetector Computed Tomography (64-절편 다행검출 CT 검사에서의 환자선량과 암 발생의 Lifetime Attributable Risk(LAR) 평가)

  • Kang, Yeong-Han;Park, Jong-Sam
    • The Journal of the Korea Contents Association
    • /
    • v.11 no.4
    • /
    • pp.244-252
    • /
    • 2011
  • This study was to estimate the radiation dose associated with 64-slice multidetector CT(MDCT) in clinical practice and quantify the potential cancer risk associated with these examinations. Lifetime attributable risks(LAR) were estimated with models developed in the national Academies' Biological Effects of Ionizing Radiation VII report. Mean effective dose were 1.48mSv in Brain axial scan, 7.66mSv in chest routine contrast, 12.17mSv in coronary angiogram, 24.52mSv in Dynamic abdomen scan. LAR estimates for brain routine varied from 1 in 7463 for man to 1 in 4926 for women. In chest routine with contrast, LAR varied from 1 in 1449 for men to 1 in 952. LAR of Abdomen dynamic CT varied from 1 in 453 for men to 1 in 298 for women. So, 64-slice MDCT scan is associated with non-negligible LAR of cancer. Doses can be reduced by careful attention to scanning protocol.

Clinical Application of 3-D Compensator in Head and Neck Cancer (두경부암 환자 치료시 3차원 보상체의 임상 적용에 대한 고찰)

  • Hong, Dong-Ki;Lee, Jeong-Woo;Lee, Koo-Hyun;Park, Kwang-Ho;Kim, Jeong-Man
    • The Journal of Korean Society for Radiation Therapy
    • /
    • v.9 no.1
    • /
    • pp.64-70
    • /
    • 1997
  • The goal of radiation treatment planning is to deliver the dose to the patient within $5\%$ of that prescribed. We have often encountered the situation that the area which have not only several irregular contours but also tissue heterogeneities should be treated. With conventional devices such as wedges, missing tissue compensator. there are some limitations to achieve the uniform dose distribution in treatment volume. The use of CT simulator, 3-D planning system, computer-controlled milling machine enables it to deliver the dose uniformally. This report includes the whole procedure which have patient data acquisition 3D planning, computer-controlled milling, performance verification of 3D compensator, and TLD evaluation. We applied it for the treatment of head and heck cancer only. In Spite of the irregular contour and different electron density of tessue, we have achieved the uniformity of the dose distribution within ${\pm}3\%$ relatively. Although there are some problems which are not only verification of performance but uncertainties of using the new treatment device, we believe that the improvement of dosimetry will eliminate the uncertainties of that application. so the other lesions besides head and neck can will be ale to use the 3D compensator to achieve the dose uniformity

  • PDF

Effects of Radiotherapy on the Risk of Developing Secondary Malignant Neoplasms in Hodgkin's Lymphoma Survivors

  • Abou-Antoun, Tamara;Mikhael, Rachelle;Massoud, Marcel;Chahine, Georges;Saad, Aline
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.17 no.2
    • /
    • pp.749-754
    • /
    • 2016
  • Extended follow-up of Hodgkin lymphoma (HL) survivors indicates that these patients are at high risk of secondary malignant neoplasms (SMNs) contributing to increased morbidity and mortality. This study examined the characteristics of HL survivors who developed SMNs with the aim to report any correlation with radiotherapy (RT) dose. In this retrospective multi-center cohort study of HL patients treated between 1990 and 2011 at three major teaching hospitals in Lebanon, classification was into two groups including those treated with combined modality (RT and chemotherapy-CHT) and those treated with CHT alone. Approval from the University Institutional Review Board (IRB) was obtained. Of the 112 patients evaluated, 52.7% (59) received the combined modality while 47.3% (53) received CHT alone. There were 6 cases of SMNs in the combined modality cohort and 5 cases in the CHT cohort. The mean RT dose in the combined modality cohort was 34.5 Gray (Gy) ($SD{\pm}5.3$). A statistically significant increase (1.5 fold) in the risk of developing SMNs was observed among patients who received a dose higher than 41 Gy compared to a dose between 20 to 30 Gy (OR= 1.5; 95% confidence interval= 0.674 to 3.339, p=0.012). The risk of SMNs was not significantly higher among patients who received extended field compared to involved field RT (p=0.964). This study showed that the risk of developing SMNs is higher among patients treated with RT dose greater than 31 Gy, independent of the RT type used.

In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost

  • Lee, Jason Joon Bock;Choi, Jinhyun;Ahn, Sung Gwe;Jeong, Joon;Lee, Ik Jae;Park, Kwangwoo;Kim, Kangpyo;Kim, Jun Won
    • Radiation Oncology Journal
    • /
    • v.35 no.2
    • /
    • pp.121-128
    • /
    • 2017
  • Purpose: To report the results of a correlation analysis of skin dose assessed by in vivo dosimetry and the incidence of acute toxicity. This is a phase 2 trial evaluating the feasibility of intraoperative radiotherapy (IORT) as a boost for breast cancer patients. Materials and Methods: Eligible patients were treated with IORT of 20 Gy followed by whole breast irradiation (WBI) of 46 Gy. A total of 55 patients with a minimum follow-up of 1 month after WBI were evaluated. Optically stimulated luminescence dosimeter (OSLD) detected radiation dose delivered to the skin during IORT. Acute toxicity was recorded according to the Common Terminology Criteria for Adverse Events v4.0. Clinical parameters were correlated with seroma formation and maximum skin dose. Results: Median follow-up after IORT was 25.9 weeks (range, 12.7 to 50.3 weeks). Prior to WBI, only one patient developed acute toxicity. Following WBI, 30 patients experienced grade 1 skin toxicity and three patients had grade 2 skin toxicity. Skin dose during IORT exceeded 5 Gy in two patients: with grade 2 complications around the surgical scar in one patient who received 8.42 Gy. Breast volume on preoperative images (p = 0.001), ratio of applicator diameter and breast volume (p = 0.002), and distance between skin and tumor (p = 0.003) showed significant correlations with maximum skin dose. Conclusions: IORT as a boost was well-tolerated among Korean women without severe acute complication. In vivo dosimetry with OSLD can help ensure safe delivery of IORT as a boost.